Efficacy and Safety of Dolutegravir With Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy oIMPAACT 2010/VESTEDTHORN: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial

被引：0
|
作者：
Aquino, Marcella
机构：
来源：
PEDIATRICS | 2021年 / 148卷
关键词：
D O I：
10.1542/peds.2021-053843YYYY
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [21] Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
    Mayer, Kenneth H.
    Molina, Jean-Michel
    Thompson, Melanie A.
    Anderson, Peter L.
    Mounzer, Karam C.
    De Wet, Joss J.
    DeJesus, Edwin
    Jessen, Heiko
    Grant, Robert M.
    Ruane, Peter J.
    Wong, Pamela
    Ebrahimi, Ramin
    Zhong, Lijie
    Mathias, Anita
    Callebaut, Christian
    Collins, Sean E.
    Das, Moupali
    McCallister, Scott
    Brainard, Diana M.
    Brinson, Cynthia
    Clarke, Amanda
    Coll, Pep
    Post, Frank A.
    Hare, C. Bradley
    LANCET, 2020, 396 (10246): : 239 - 254
  • [22] Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China
    Sun, Liqin
    He, Yun
    Xu, Liumei
    Zhao, Fang
    Zhou, Yang
    Zhang, Lukun
    Peng, Qiaoli
    Zhang, Haitao
    Zhang, Qiuyue
    Cao, Tingzhi
    Song, Ying
    Wang, Siyuan
    Rao, Man
    Jia, Xinyun
    Liu, Xiaoning
    Zhou, Jing
    Ju, Bin
    Wang, Hui
    Liu, Jiaye
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 : S8 - S15
  • [23] Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate/rivaroxabanLack of efficacy due to interaction and off-label use: case report
    Reactions Weekly, 2021, 1869 (1) : 142 - 142
  • [24] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
    Cicalini, S.
    Lorenzini, P.
    Grilli, E.
    Plazzi, M. M.
    De Zottis, F.
    Camici, M.
    Fusto, M.
    Gagliardini, R.
    Bellagamba, R.
    Antinori, A.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [25] Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment
    Wilkins, Ed L.
    Cohen, Calvin J.
    Trottier, Benoit
    Esser, Stefan
    Smith, Don E.
    Haas, Bernhard
    Brinson, Cynthia
    Garner, Will
    Chuck, Susan
    Thorpe, David
    De-Oertel, Shampa
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2016, 28 (03): : 401 - 408
  • [26] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    HIV MEDICINE, 2020, 21 : 12 - 12
  • [27] Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
    Chang, Young
    Kim, Sang-Gyune
    Jeong, Soung-Won
    Jang, Jae-Young
    Yoo, Jeong-Ju
    Lee, Sae-Hwan
    Kim, Young-Seok
    Kim, Hong-Soo
    Lee, Hyun-Woong
    Park, Suyeon
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [28] DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)
    Post, F.
    Spinner, C.
    Coll, P.
    Hawkins, T.
    Anderson, J.
    Zhong, L.
    McCallister, S.
    HIV MEDICINE, 2019, 20 : 243 - 244
  • [29] Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Martorell, Claudia T.
    de Wet, Joseph
    Stellbrink, Hans-Jurgen
    Molina, Jean-Michel
    Post, Frank A.
    Valero, Ignacio Perez
    Porter, Danielle
    Liu, Yapei
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    LANCET HIV, 2017, 4 (05): : E205 - E213
  • [30] Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz: An Open-Label, Randomized Controlled Trial
    Boontanondha, Patawee
    Nimitphong, Hataikarn
    Musikarat, Suchawadee
    Ragkho, Aschara
    Kiertiburanakul, Sasisopin
    CURRENT HIV RESEARCH, 2020, 18 (01) : 52 - 62
12345